Cytek Biosciences, Inc. (CTKB)

NASDAQ: CTKB · IEX Real-Time Price · USD
13.74 0.00 (0.00%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap1.84B
Revenue (ttm)119.68M
Net Income (ttm)3.06M
Shares Out133.73M
EPS (ttm)0.01
PE Ratio1,374.00
Forward PE370.37
Dividendn/a
Ex-Dividend Daten/a
Volume98,062
Open13.57
Previous Close13.74
Day's Range13.14 - 13.83
52-Week Range13.14 - 28.70
Betan/a
AnalystsBuy
Price Target25.00 (+82.0%)
Earnings DateNov 8, 2021

About CTKB

Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications. We believe our core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell analysis by utilizing the full ...

IndustryMedical Devices
IPO DateJul 23, 2021
CEOWenbin Jiang, Ph.D.
Employees462
Stock ExchangeNASDAQ
Ticker SymbolCTKB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CTKB stock is "Buy." The 12-month stock price forecast is 25.00, which is an increase of 81.95% from the latest price.

Price Target
$25.00
(81.95% upside)
Analyst Consensus: Buy

News

Cytek® Biosciences Expands Fremont Headquarters, Tripling Its Manufacturing Capacity

Operations to Accommodate Increasing Demand for Cell Analysis Solutions Operations to Accommodate Increasing Demand for Cell Analysis Solutions

1 week ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Cytek Biosciences, Inc. (CTKB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreemen...

1 month ago - Zacks Investment Research

Cytek® Biosciences Marks Milestone Achievement with Shipment of 1000th Cell Analysis System

Company Continues Forward Momentum Following IPO, Expanded Product Portfolio and Increased Global Footprint Company Continues Forward Momentum Following IPO, Expanded Product Portfolio and Increased Glo...

1 month ago - GlobeNewsWire

Cytek Biosciences Reports Third Quarter 2021 Financial Results

Third quarter total revenue growth of 37% compared to prior year Third quarter total revenue growth of 37% compared to prior year

2 months ago - GlobeNewsWire

Cytek Biosciences Acquires Tonbo Biosciences' Cell Analysis Business

FREMONT, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that it has acquired the cell analysis business of...

2 months ago - GlobeNewsWire

Cytek Biosciences to Report Third Quarter Financial Results on November 8, 2021

FREMONT, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2021 af...

2 months ago - GlobeNewsWire

Cytek® Biosciences Introduces New 25-Color Immunoprofiling Assay

Optimized for Cytek Aurora Cell Analysis Systems; Delivers Turnkey Solution for Immunophenotyping Optimized for Cytek Aurora Cell Analysis Systems; Delivers Turnkey Solution for Immunophenotyping

3 months ago - GlobeNewsWire

Cytek Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today announced the company will be participating in the Morgan Stanley 19th A...

4 months ago - GlobeNewsWire

Cytek Biosciences Reports Second Quarter 2021 Financial Results

FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2021.

4 months ago - GlobeNewsWire

Cytek Biosciences Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

FREMONT, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that the underwrite...

5 months ago - GlobeNewsWire

Cytek Biosciences Announces Closing of Its Initial Public Offering

FREMONT, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today the closing of its ...

5 months ago - GlobeNewsWire